{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-039316","form_type":"8-K","ticker":"ACLX","cik":"0001786205","company_name":"Arcellx, Inc.","filed_at":"2025-02-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.856161+00:00","generated_at":"2026-05-26T02:23:16.588590+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Arcellx FY2024 net loss $107.3M; anito-cel Phase 2 shows 97% ORR, 62% CR/sCR","bullets":["Cash, equivalents, and marketable securities $625.7M; runway into 2027.","Collaboration revenue $107.9M in FY2024 vs $110.3M in FY2023.","Net loss $107.3M for FY2024 vs $70.7M prior year; R&D spend $157.1M.","Anito-cel pivotal iMMagine-1 data: 97% ORR, 62% CR/sCR (n=86), no delayed neurotoxicities.","Commercial launch of anito-cel in RRMM planned for 2026; iMMagine-1 update mid-2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-039316","json":"https://secwatch.observer/filing/0001193125-25-039316.json","markdown":"https://secwatch.observer/filing/0001193125-25-039316.md","text":"https://secwatch.observer/filing/0001193125-25-039316.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1786205/000119312525039316/0001193125-25-039316-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1786205/000119312525039316/d904514d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T02:23:16.588590+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}